Buys royalties on biopharmaceutical therapies.
Jun 2026Revenue $2.54B/yrExpenses $1.02B/yr
No trend
Figures by year
Is Royalty Pharma profitable?
Yes. In the 12 months to Jun 2026, revenue was $2.54B and expenses $1.02B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.38B | $819M | $1.56B |
| Dec 2024 | $2.26B | $971M | $1.29B |
| Dec 2023 | $2.35B | $862M | $1.49B |
| Dec 2022 | $2.24B | $1.93B | $307M |
| Dec 2021 | $2.29B | $859M | $1.43B |
| Dec 2020 | $2.12B | $527M | $1.60B |
| Dec 2019 | $1.81B | −$809M | $2.62B |
| Dec 2018 | $1.79B | $430M | $1.36B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.